In the pembrolizumab arm, the association of baseline tumor-informed maxVAF with PFS and OS were robust to the adjustment for baseline tumor size and tTMB and PD-L1 status in both metrics (P < 0.01); BOR was no longer associated after adjustment (P > 0.05; Fig. 1). The gene discussed is CD274; the disease is neoplasm.